NCT05397223View on ClinicalTrials.gov

A Study of Modified mRNA Vaccines in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

February 21, 2026

Study Completion Date

February 21, 2026

Conditions
SARS-CoV-2Seasonal InfluenzaRespiratory Syncytial VirusCytomegalovirus
Interventions
BIOLOGICAL

mRNA-1273

Sterile liquid for injection

BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

mRNA-1345

Sterile liquid for injection

BIOLOGICAL

FLUAD®

adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine

BIOLOGICAL

mRNA-1647

Sterile lyophilized product

Trial Locations (8)

31406

Meridian Clinical Research, Savannah

33024

CenExel, Hollywood

51106

Meridian Clinical Research, Sioux City

66219

Johnson County Clinical Trials, Lenexa

68510

Meridian Clinical Research, Lincoln

77081

DM Clinical Research- Texas Center for Drug Development, Houston

78705

Benchmark Research, Austin

78745

Tekton Research, Inc, Austin

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY